JLL Partners poised for 60-plus-pct IRR on Patheon exit

JLL Partners, Patheon NV, Thermo Fisher Scientific, healthcare, private equity, merger, M&A
Medicines on a shelf of a prescription pharmacy is seen through its window in Tokyo, Japan, December 20, 2016. REUTERS/Kim Kyung-Hoon - RTX2VT9Y
  • JLL acquired 51 pct stake in Patheon in 2014
  • Most of firm’s equity came from Fund VI
  • Deal values Patheon at $3.8 bln
JLL Partners stands to make 4x to 5x its investment in Patheon NV, according to a source with knowledge of the deal. Thermo Fisher Scientific is expected to close its acquisition of the drug-manufacturing business in the next three to five ...
FUNDRAISERS: Don't miss Emerging Manager Connect West 2018 in San Francisco on May 1! CLICK FOR DETAILS!

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition


To read a digital copy of our latest magazine

click here

PE News Briefs